brain degeneration in 676 subjects with impairment, and healthy controls
|
|
- Judith Stewart
- 5 years ago
- Views:
Transcription
1 Neroimaging i biomarkers track brain degeneration in 676 sbjects with Alheimer s disease, mild cognitive impairment, and health controls Laborator of Nero Imaging Xe Ha, Sh Lee, Ale Leow, Igor Yanovsk, Arthr W. Toga, Michael W. Wi Weiner, Pal lm. Thompson, et. al. and the Alheimer's Disease Neroimaging Initiative
2 Alheimer's Disease Neroimaging Initiative (ADNI) ADNI is a large five ear research project 200 AD, 400 MCI and 200 elderl controls info.org/
3 Tensor Based Morphometr (TBM) l Cross sectional Design,, MDT I di id ls Jacobian Map MDT Individal Scan ( ) ( ) ( ) ( ) ( ) ( ) J ( ) ( ) ( ) ( ) ( ) ( ) = J ( ) Epansion Volme r J 1 det > ( ) Loss Volme r J 1 det <
4 Tracking brain degeneration in 676 sbjects with AD (N=165), MCI (N=330), and health controls (N=181) AD vs. CTL MCI vs. CTL AD vs. MCI Ha X, Toga AW, Thompson PM, et al. (2008) Neroimage 43(3):
5 Baseline TBM correlate with Sm of Boes CDR Baseline TBM correlate with FUTURE CHANGES in Sm of Boes CDR Ha X, Toga AW, Thompson PM, et al. (2008) Neroimage 43(3):
6 Baseline TBM correlate with MMSE Baseline TBM correlate with FUTURE CHANGES in MMSE Ha X, Toga AW, Thompson PM, et al. (2008) Neroimage 43(3):
7 Association between Jacobian vales and conversion to AD in a ear 40 MCI sbjects became AD after a ear, corresponding to a conversion rate of 21.5% Ha X, Toga AW, Thompson PM, et al. (2008) Neroimage 43(3):
8 ApoE and brain strctre Ha X, Toga AW, Thompson PM, et al. (2008) Neroimage 43(3):
9 Tensor Based Morphometr (TBM) Longitdinal Design MDT,, Baseline 12 mo Jacobian Map ( ) ( ) ( ) J = ( ) ( ) ( ) ( ) ( ) ( ) ( r ) Volme Epansion det J > 1 ( r) Volme Loss det J < 1
10 AD (N=104) verss Normal (N=157) Mean Atroph Rates Ha X, Toga AW, Thompson PM, et al. (2009) Neroimage 48(4):
11 MCI (N=254) verss Normal (N=157) Mean Atroph Rates Ha X, Toga AW, Thompson PM, et al. (2009) Neroimage 48(4):
12 Region of interest of interest (ROI) Temporal lobes Statistical ROI derived from an independent training sample of 22 AD patients Ha X, Toga AW, Thompson PM, et al. (2009) Neroimage 48(4):
13 Estimated sample sies (n80) needed to detect a 25% redction in the mean annal change with a two sided test and α=0.05 at 80% power, for a two arm std n = ˆ ( + ) 2 2 2σ D 1 α / 2 power ( 0.25 ˆ β ) 2 Sm of boesclinical Dementia Rating (CDR) gives best power among the clinical scores, bt the TBM method is 9 times better AD MCI TBM CDR-SB ADAS-Cog MMSE Ha X, Toga AW, Thompson PM, et al. (2009) Neroimage 48(4):
14 The rates of temporal lobe atroph correlate with the levelsof CSF biomarkers A longitdinal std of 100 sbjects (20 AD, 40 MCI and 20 controls) Leow AD, Ha X, Toga AW, Thompson PM, et al. (2009) Neroimage 45(3):
15 Smmar TBM as a neroimaging marker Correlate with clinical decline, CSF biomarkers, and predict ftre conversion to AD Ui Using TBM as a potential ti srrogate marker, onl 48 AD and 88 MCI sbjects are needed to detect t 25% slowing of disease in clinical i l trials (9 better than best clinical score)
16 Acknowledgements UCLA ADNI Team Pal Thompson PhD (PI) Arthr Toga PhD (PI) ShLee Igor Yanovsk PhD Ale D. Leow MD PhD Ming Chang Chiang Yi Y Cho MS April J. Ho Boris Gtman Non UCLA Collaborators Clifford R. Jack Jr MD Matt A. Bernstein PhD Eric M. Reiman MD Danielle Harve PhD John Kornak PhD Norbert Schff PhD Gene E. Aleander PhD Michael W. Weiner MD ADNI (PI: Michael Weiner; NIH grant nmber U01 AG024904) National Institte of Aging National Institte of Biomedical Imaging and Bioengineering (NIBIB) Fondation for the National Instittes of Health, Pfier Inc. Weth Research Bristol Mers Sqibb Eli Lill and Compan GlaoSmithKline Merck & Co. Inc. AstraZeneca AB Novartis Pharmaceticals Corporation Alheimer s Association Eisai Global Clinical Development Elan Corporation plc, Forest Laboratories Institte for the Std of Aging (ISOA), U.S. Food and Drg Administration Algorithm development was also fnded b the NIA, NIBIB, the National Librar of Medicine, and the National Center for Research Resorces (AG016570, EB01651, LM05639, RR to PT).
NIH Public Access Author Manuscript Neuroreport. Author manuscript; available in PMC 2012 June 11.
NIH Public Access Author Manuscript Published in final edited form as: Neuroreport. 2011 June 11; 22(8): 391 395. doi:10.1097/wnr.0b013e328346bf85. Homocysteine effects on brain volumes mapped in 732 elderly
More informationNeuroReport 2011, 22: a Laboratory of Neuro Imaging, Department of Neurology, UCLA School of. Received 9 March 2011 accepted 13 March 2011
Ageing 391 Homocysteine effects on brain volumes mapped in 732 elderly individuals Priya Rajagopalan a, Xue Hua a, Arthur W. Toga a, Clifford R. Jack Jr b, Michael W. Weiner c,d and Paul M. Thompson a
More informationNIH Public Access Author Manuscript Neuroimage. Author manuscript; available in PMC 2010 May 15.
NIH Public Access Author Manuscript Published in final edited form as: Neuroimage. 2010 May 15; 51(1): 63 75. doi:10.1016/j.neuroimage.2010.01.104. Mapping Alzheimer s disease progression in 1309 MRI scans:
More informationNeuroImage 43 (2008) Contents lists available at ScienceDirect. NeuroImage. journal homepage:
NeuroImage 43 (2008) 458 469 Contents lists available at ScienceDirect NeuroImage journal homepage: www.elsevier.com/locate/ynimg Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease:
More informationNeuroImage 45 (2009) Contents lists available at ScienceDirect. NeuroImage. journal homepage:
NeuroImage 45 (2009) 645 655 Contents lists available at ScienceDirect NeuroImage journal homepage: www.elsevier.com/locate/ynimg Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study
More informationWWADNI MRI Core Boston July 2013
WWADNI MRI Core Boston July 2013 Bret Borowski - Mayo Matt Bernstein - Mayo Jeff Gunter Mayo Clifford Jack - Mayo David Jones - Mayo Kejal Kantarci - Mayo Denise Reyes Mayo Matt Senjem Mayo Prashanthi
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationSubmitted to NeuroImage: December 3, 2007 Revised Version submitted: February 9, nd Revision submitted: May 26, 2008
Validation of a Fully Automated 3D Hippocampal Segmentation Method Using Subjects with Alzheimer s Disease, Mild Cognitive Impairment, and Elderly Controls Jonathan H. Morra MS 1, Zhuowen Tu PhD 1, Liana
More informationMRI WWADNI Copenhagen 2014
MRI WWADNI Copenhagen 2014 Bret Borowski - Mayo Matt Bernstein - Mayo Jeff Gunter Mayo Clifford Jack - Mayo David Jones - Mayo Kejal Kantarci - Mayo Denise Reyes Mayo Matt Senjem Mayo Prashanthi Vemuri
More informationNIH Public Access Author Manuscript Neuroimage. Author manuscript; available in PMC 2009 June 16.
NIH Public Access Author Manuscript Published in final edited form as: Neuroimage. 2009 April 15; 45(3): 645 655. doi:10.1016/j.neuroimage.2009.01.004. Alzheimer s Disease Neuroimaging Initiative: A one-year
More informationIndiana University School of Medicine, Indianapolis, IN USA 1
GWAS and Candidate Studies of MRI and Amyloid PET Phenotypes for Alzheimer's Disease Andrew J. Saykin Depts. of Radiology & Imaging Sciences and Medical & Molecular Genetics, Neurology & Psychiatry; Indiana
More informationDetection of Mild Cognitive Impairment using Image Differences and Clinical Features
Detection of Mild Cognitive Impairment using Image Differences and Clinical Features L I N L I S C H O O L O F C O M P U T I N G C L E M S O N U N I V E R S I T Y Copyright notice Many of the images in
More informationRaymond Y. Lo, MD, MS William J. Jagust, MD For the Alzheimer s Disease Neuroimaging Initiative
ARTICLES Predicting missing biomarker data in a longitudinal study of Alzheimer disease Raymond Y. Lo, MD, MS William J. Jagust, MD For the Alzheimer s Disease Neuroimaging Initiative Correspondence &
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationOn cognitive performance as endpoint in clinical trials Ben Schmand
On cognitive performance as endpoint in clinical trials Ben Schmand Department of Neurology, Academic Medical Center Department of Psychology, University of Amsterdam The Netherlands What are the best
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationARTICLE IN PRESS. Introduction
YNIMG-05259; No. of pages: 16; 4C: 1 www.elsevier.com/locate/ynimg NeuroImage xx (2008) xxx xxx 2 3D characterization of brain atrophy in alzheimer's disease and mild 3 cognitive impairment using tensor-based
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2012 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader October 2011 The Australian Imaging Biomarkers
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationTOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION. Paul S. Aisen, MD Department of Neurosciences University of California, San Diego
TOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION Paul S. Aisen, MD Department of Neurosciences University of California, San Diego Brief History of AD Therapeutics 1906: Dr. Alois Alzheimer
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationNIH Public Access Author Manuscript AJNR Am J Neuroradiol. Author manuscript; available in PMC 2014 January 16.
NIH Public Access Author Manuscript Published in final edited form as: AJNR Am J Neuroradiol. 2013 December ; 34(12): 2287 2293. doi:10.3174/ajnr.a3601. Higher Rates of Decline for Women and APOE ε4 Carriers
More informationMolecular Imaging Heterogeneity of Clinically Defined AD
Molecular Imaging Heterogeneity of Clinically Defined AD Gil Rabinovici, M.D. Edward Fein & Pearl Landrith Endowed Professor UCSF Memory & Aging Center 2017 Spring ADC Meeting Boston, MA April 22, 2017
More informationEngineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
More informationNIH Public Access Author Manuscript Neuroimaging Clin N Am. Author manuscript; available in PMC 2008 May 12.
NIH Public Access Author Manuscript Published in final edited form as: Neuroimaging Clin N Am. 2005 November ; 15(4): 869 xii. The Alzheimer s Disease Neuroimaging Initiative Susanne G. Mueller, MD a,
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationA Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing.
A Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing. Dean Hartley, Ph.D., Alzheimer's Association, Emily Drabant, Ph.D., 23 and me, Anne Wojcicki, 23 and me, Rob Fetherstonhaugh,
More informationRandomized controlled trials in mild cognitive impairment Sources of variability
Randomized controlled trials in mild cognitive impairment Sources of variability Ronald C. Petersen, PhD, MD Ronald G. Thomas, PhD Paul S. Aisen, MD Richard C. Mohs, PhD Maria C. Carrillo, PhD Marilyn
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationADNI PET CORE. Boston April Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price
ADNI PET CORE Boston April 27 Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price ADNI Florbetapir scan counts Number of Florbetapir scans N SMC EMCI LMCI AD Total
More informationWashington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease
Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement
More informationEXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationNIH Public Access Author Manuscript Alzheimers Dement. Author manuscript; available in PMC 2011 May 1.
NIH Public Access Author Manuscript Published in final edited form as: Alzheimers Dement. 2010 May ; 6(3): 257 264. doi:10.1016/j.jalz.2010.03.002. The Alzheimer s Disease Neuroimaging Initiative: Annual
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationA REVIEW: ON METHODS OF DETECTION FOR ALZHEIMER S DEMENTIA USING BIOINFORMATICS TOOLS Oieswarya Bhowmik 1, M.
ISSN: 0975-766X CODEN: IJPTFI Available Online through Review Article www.ijptonline.com A REVIEW: ON METHODS OF DETECTION FOR ALZHEIMER S DEMENTIA USING BIOINFORMATICS TOOLS Oieswarya Bhowmik 1, M. Murali
More informationAdvance Care Planning in the Chronic Kidney Disease Population A Quality Improvement Project
Advance Care Planning in the Chronic Kidney Disease Poplation A Qality Improvement Project BARBARA WEIS MALONE DNP, FNP-C, FNKF ASSOCIATE PROFESSOR, UNIVERSITY OF COLORADO COLLEGE OF NURSING 2017 TENTH
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development Wm Z Potter, MD, PhD Sr. Advisor, NIMH IOM, Nov 15, 2014 Disclosures Former employee of Lilly
More informationNeuroImage 51 (2010) Contents lists available at ScienceDirect. NeuroImage. journal homepage:
NeuroImage 51 (2010) 488 499 Contents lists available at ScienceDirect NeuroImage journal homepage: www.elsevier.com/locate/ynimg Automated 3D mapping of baseline and 12-month associations between three
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationSparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data
Ye et al. BMC Neurology 2012, 12:46 RESEARCH ARTICLE Open Access Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data Jieping Ye 1*, Michael Farnum 2, Eric
More informationarxiv: v1 [cs.lg] 13 Mar 2018
A Probabilistic Disease Progression Model for Predicting Future Clinical Outcome Yingying Zhu Electrical and Computer Eng, Cornell Ithaca, NY, USA yz2377@cornell.edu Mert R. Sabuncu Electrical and Computer
More informationCognitive reserve associated with FDG-PET in preclinical Alzheimer disease
Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease Michael Ewers, Philip S. Insel, Yaakov Stern, et al. Neurology 2013;80;1194; Published online before print March 13, 2013; DOI
More informationNIH Public Access Author Manuscript Alzheimers Dement. Author manuscript; available in PMC 2012 September 1.
NIH Public Access Author Manuscript Published in final edited form as: Alzheimers Dement. 2011 September ; 7(5): 514 520. doi:10.1016/j.jalz.2010.12.010. Impact of APOE4-CSF Aβ interaction on hippocampal
More informationIdentification of novel cortical surface biomarkers for predicting cognitive outcomes based on group-level `2,1 norm
Identification of novel cortical surface biomarkers for predicting cognitive outcomes based on group-level `2,1 norm Jingwen Yan 1,2, Taiyong Li 1,3, Hua Wang 4, Heng Huang 4,?, Jing Wan 1,5, Kwangsik
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 Passed by Congress 2010 December January 2011
More informationTemporally-Constrained Group Sparse Learning for Longitudinal Data Analysis in Alzheimer s Disease
TBME-00121-2015 1 Temporally-Constrained Group Sparse Learning for Longitudinal Data Analysis in Alzheimer s Disease Biao Jie, Mingxia Liu, Jun Liu, Daoqiang Zhang * and Dinggang Shen *, the Alzheimer
More informationNeuroImage 59 (2012) Contents lists available at SciVerse ScienceDirect. NeuroImage. journal homepage:
NeuroImage 9 (212) 89 97 Contents lists available at SciVerse ScienceDirect NeuroImage journal homepage: www.elsevier.com/locate/ynimg Multi-modal multi-task learning for joint prediction of multiple regression
More informationMachine Learning Algorithms for Neuroimaging-based Clinical Trials in Preclinical Alzheimer s Disease
Machine Learning Algorithms for Neuroimaging-based Clinical Trials in Preclinical Alzheimer s Disease Vamsi K. Ithapu Wisconsin Alzheimer s Disease Research Center University of Wisconsin-Madison April
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationbiomarker may improve the efficiency of a study, and simulations may help in planning studies Requiring an amyloid-β 1 42 VIEWPOINT Suzanne B Hendrix*
VIEWPOINT Requiring an amyloid-β 1 42 biomarker may improve the efficiency of a study, and simulations may help in planning studies Suzanne B Hendrix* Abstract A recent article by Schneider and colleagues
More informationTranslating pilot studies into larger clinical trials Twelve Commandments Marco Pahor, MD University of Florida Institute on Aging.
Translating pilot studies into larger clinical trials Twelve Commandments Marco Pahor, MD University of Florida Institute on Aging www.aging.ufl.edu Twelve Commandments to achieve large clinical trials
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationThe structural MRI markers and cognitive decline in prodromal Alzheimer s disease: a 2-year longitudinal study
Original Article The structural MRI markers and cognitive decline in prodromal Alzheimer s disease: a 2-year longitudinal study Hongchun Wei 1#, Min Kong 2#, Chunhua Zhang 1, Lina Guan 1, Maowen Ba 1 ;
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationA perspective on preclinical Alzheimer's disease trials
A perspective on preclinical Alzheimer's disease trials Pierre N. Tariot, MD Director, Banner Alzheimer s Institute Co-Director, API Research Professor of Psychiatry University of Arizona Disclosures I
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationStructural MRI in Frontotemporal Dementia: Comparisons between Hippocampal Volumetry, Tensor- Based Morphometry and Voxel-Based Morphometry
: Comparisons between Hippocampal Volumetry, Tensor- Based Morphometry and Voxel-Based Morphometry Miguel Ángel Muñoz-Ruiz 1,Päivi Hartikainen 1,2, Juha Koikkalainen 3, Robin Wolz 4, Valtteri Julkunen
More informationCAMD & FDA 2015 Annual Scientific Workshop. October 15, 2015 / FDA White Oak Campus
CAMD & FDA 2015 Annual Scientific Workshop Alzheimer s Disease CSF Biomarker Working Group October 15, 2015 / FDA White Oak Campus AD CSF Biomarker Project Team AbbVie Just Genius, Jeff Waring, Leslie
More informationHHS Public Access Author manuscript JAMA Neurol. Author manuscript; available in PMC 2017 October 02.
HHS Public Access Author manuscript Published in final edited form as: JAMA Neurol. 2016 January ; 73(1): 60 67. doi:10.1001/jamaneurol.2015.3037. Association of Cerebrospinal Fluid Neurofilament Light
More informationMRI Hippocampal Volume for Enrichment
MRI Hippocampal Volume for Enrichment Derek Hill 1,2 & Jerry Novak 3, Pat Cole 4, Diane Stephenson 5 1. IXICO plc 2. UCL, London, UK 3. Johnson and Johnson 4. Takeda 5. CAMD, Critical Path Institute 1
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory
More informationSubject Index. Berkson bias 72
Subject Index AAAT study 62 Absolute risk reduction (ARR) 40 ACCORD study 62 AD, see Alzheimer s disease ADVANCE study 62 ALLHAT study 62 ALS, see Amyotrophic lateral sclerosis Alzheimer s disease (AD)
More informationORIGINAL CONTRIBUTION. Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative
ORIGINAL CONTRIBUTION Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative Owen Carmichael, PhD; Christopher Schwarz; David Drucker;
More informationUC Irvine UC Irvine Previously Published Works
UC Irvine UC Irvine Previously Published Works Title MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials Permalink https://escholarship.org/uc/item/50d8c8xr
More informationMultilayer clustering: Biomarker driven segmentation of Alzheimer s disease patient population
Multilayer clustering: Biomarker driven segmentation of Alzheimer s disease patient population Dragan Gamberger Rudjer Bošković Institute, Zagreb, Croatia Bernard Ženko Jožef Stefan Institute, Ljubljana,
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationBiogen, Cambridge, MA, USA; 2 Cytel, Cambridge, MA, USA; 3 Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer s Disease Samantha Budd Haeberlein, PhD 1, Sarah Gheuens,
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationORIGINAL CONTRIBUTION. Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment Ozioma C. Okonkwo, PhD; Michelle M. Mielke, PhD; H. Randall Griffith,
More informationNIH Public Access Author Manuscript Med Image Comput Comput Assist Interv. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Med Image Comput Comput Assist Interv. 2010 ; 13(Pt 3): 611 618. Sparse Bayesian Learning for Identifying Imaging Biomarkers in AD
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationHandling Associate Editor: Maheen Adamson
Journal of Alzheimer s Disease 45 (2015) 253 268 DOI 10.3233/JAD-142451 IOS Press 253 Cognition, Brain Atrophy, and Cerebrospinal Fluid Biomarkers Changes from Preclinical to Dementia Stage of Alzheimer
More informationNIH Public Access Author Manuscript J Nucl Med. Author manuscript; available in PMC 2014 August 17.
NIH Public Access Author Manuscript Published in final edited form as: J Nucl Med. 2013 September ; 54(9): 1564 1569. doi:10.2967/jnumed.112.116137. Longitudinal Progression of Cognitive Decline Correlates
More information42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment. Gordon K. Wilcock*, University of Oxford, UK
Efficacy and Safety of Tarenflurbil (Flurizan ), a Selective Aβ42A 42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment Gordon K. Wilcock*, University of Oxford,
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationSemi-Supervised Multimodal Relevance Vector Regression Improves Cognitive Performance Estimation from Imaging and Biological Biomarkers
Neuroinform (2013) 11:339 353 DOI 10.1007/s12021-013-9180-7 ORIGINAL ARTICLE Semi-Supervised Multimodal Relevance Vector Regression Improves Cognitive Performance Estimation from Imaging and Biological
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationGlobal clinical dementia rating of 0.5 in MCI masks variability related to level of function
Global clinical dementia rating of 0.5 in MCI masks variability related to level of function Y.-L. Chang, PhD M.W. Bondi, PhD L.K. McEvoy, PhD C. Fennema-Notestine, PhD D.P. Salmon, PhD D. Galasko, MD
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More information3D pattern of brain abnormalities in Fragile X syndrome visualized using tensor-based morphometry
www.elsevier.com/locate/ynimg NeuroImage 34 (2007) 924 938 3D pattern of brain abnormalities in Fragile X syndrome visualized using tensor-based morphometry Agatha D. Lee, a Alex D. Leow, a,b Allen Lu,
More informationNIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2011 December 31.
NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2011 August ; 68(8): 1040 1048. doi:10.1001/archneurol.2011.167. The Dynamics of Cortical and Hippocampal Atrophy in
More informationApplication of Item Response Theory to ADAS-cog Scores Modeling in Alzheimer s Disease
Application of Item Response Theory to ADAS-cog Scores Modeling in Alzheimer s Disease Sebastian Ueckert 1, Elodie L. Plan 2, Kaori Ito 3, Mats O. Karlsson 1, Brian W. Corrigan 3, Andrew C. Hooker 1 1.
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationNutrition and Water for Dementia Prevention
台日生技醫藥研討會 - 自然療法於失智症預防及照護之應用 Nutrition and Water for Dementia Prevention 胡朝榮 Chaur-Jong Hu, M.D. Professor and Direction, Department of Neurology and Dementia Center, Shuang Ho Hospital, Taipei Medical
More informationCAMD Annual Regulatory Science Workshop CSF Biomarker Team Refocusing on Low Hanging Fruit
CAMD Annual Regulatory Science Workshop CSF Biomarker Team Refocusing on Low Hanging Fruit October 19, 2016 Mary Savage, Co-Chair (seeking additional co-chair) Director, Companion Diagnostics Merck & Co.,
More informationNIH Public Access Author Manuscript J Int Neuropsychol Soc. Author manuscript; available in PMC 2014 September 23.
NIH Public Access Author Manuscript Published in final edited form as: J Int Neuropsychol Soc. 2014 September ; 20(8): 836 847. doi:10.1017/s135561771400068x. Subjective Cognitive Complaints Contribute
More informationImplementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative Leslie M Shaw Perelman School of Medicine, University of Pennsylvania
More informationDietary Supplements, Caffeine, and Cognitive Aging
Institute of Medicine Committee on the Public Health Dimensions of the National Academies Beckman Center of the National Academies Irvine, CA June 9, 2014 Dietary Supplements, Caffeine, and Cognitive Aging
More informationNeuroImage xxx (2010) xxx xxx. Contents lists available at ScienceDirect. NeuroImage. journal homepage:
YNIMG-07212; No. of pages: 10; 4C: NeuroImage xxx (2010) xxx xxx Contents lists available at ScienceDirect NeuroImage journal homepage: www.elsevier.com/locate/ynimg Measurement of hippocampal atrophy
More informationSecondary prevention of Alzheimer s dementia: neuroimaging contributions
ten Kate et al. Alzheimer's Research & Therapy (2018) 10:112 https://doi.org/10.1186/s13195-018-0438-z RESEARCH Open Access Secondary prevention of Alzheimer s dementia: neuroimaging contributions Mara
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationGenetic Heterogeneity of Clinically Defined AD. Andrew J. Saykin, PsyD Indiana ADC ADC Clinical Core Leaders Meeting April 22, 2017
Genetic Heterogeneity of Clinically Defined AD Andrew J. Saykin, PsyD Indiana ADC ADC Clinical Core Leaders Meeting April 22, 2017 Disclosures & Acknowledgements Disclosures Eli Lilly (Collaborative Grant),
More informationAACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM. Sherwin D Souza, MD, FACE
AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM Sherwin D Soza, MD, FACE Prediabetes Treatment Algorithm T2DM = type 2 diabetes mellits BP = blood pressre CVD = cardiovasclar disease
More informationMild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm?
Mild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm? Constantine G. Lyketsos, MD, MHS Chair of Psychiatry, Johns Hopkins Bayview Elizabeth Plank Althouse Professor, Johns Hopkins University
More information